TReat-to-tArget (T2T) with seCukinumab in axial spondyloarthritis. IdEntification of MRI and biochemical biomarkers for disease activity, treatment response and structural damage progression (the TRACE study) (Videnskabeligt studie af behandlings-algoritme med Cosentyx til patienter med rygsØjlegigt. Identifikation af MR- og biokemiske markØrer for sygdomsaktivitet, behandlingsrespons og udvikling af strukturel knogleskade) (TRACE studiet)

Trial Profile

TReat-to-tArget (T2T) with seCukinumab in axial spondyloarthritis. IdEntification of MRI and biochemical biomarkers for disease activity, treatment response and structural damage progression (the TRACE study) (Videnskabeligt studie af behandlings-algoritme med Cosentyx til patienter med rygsØjlegigt. Identifikation af MR- og biokemiske markØrer for sygdomsaktivitet, behandlingsrespons og udvikling af strukturel knogleskade) (TRACE studiet)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Secukinumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
  • Indications Ankylosing spondylitis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms TRACE
  • Most Recent Events

    • 07 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top